{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"}],"units":"Participants"}],"description":"Grade 2 adverse event is moderate.","groups":[{"description":"1x10\\^11 E7 TCR T cells will be administered intravenously over 20 to 30 minutes on day 0.\n\nE7 T Cell Receptor (TCR): One dose of E7 TCR T cells (1x10\\^11 cells) will be administered intravenously over 20 to 30 minutes.","id":"OG000","title":"Arm 1/1x10^11 E7 T Cell Receptor (TCR) T Cells"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"30 days following the last dose of study therapy","title":"Number of Grade 2 Adverse Events Unlikely Related to Drug in Participants Who Received E7 T-Cell Receptor (TCR) T Cells Administered in a Low Intensity Setting Without Conditioning or Systemic Aldesleukin","type":"SECONDARY","unitOfMeasure":"adverse events"}